• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    12/17/21 4:38:20 PM ET
    $AMRX
    $ASLN
    $BBI
    $BLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMRX alert in real time by email

     

    Gainers

    • GBS (NASDAQ:GBS) stock rose 14.28% to $1.44 during Friday's after-market session. At the close, GBS's trading volume reached 299.7K shares. This is 34.56% of its average volume over the last 100 days. The market value of their outstanding shares is at $21.4 million.
    • Brickell Biotech (NASDAQ:BBI) shares moved upwards by 11.11% to $0.26. Trading volume for this security closed at 527.2K, accounting for 20.85% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $29.6 million.
    • Zosano Pharma (NASDAQ:ZSAN) stock rose 6.66% to $0.54. Zosano Pharma's trading volume hit 130.4K shares by close, accounting for 5.99% of its average volume over the last 100 days. The company's market cap stands at $64.3 million.
    • Corvus Pharmaceuticals (NASDAQ:CRVS) stock moved upwards by 5.86% to $2.89. Corvus Pharmaceuticals's trading volume hit 68.3K shares by close, accounting for 0.81% of its average volume over the last 100 days. The company's market cap stands at $134.5 million.
    • Amneal Pharmaceuticals (NYSE:AMRX) shares rose 5.85% to $4.52. At the close, Amneal Pharmaceuticals's trading volume reached 317.8K shares. This is 37.96% of its average volume over the last 100 days. The market value of their outstanding shares is at $675.1 million.
    • Venus Concept (NASDAQ:VERO) stock moved upwards by 5.55% to $1.52. Today's trading volume for this security ended up closing at 97.6K shares, which is 44.14 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $82.3 million.

    Losers

    • ZIOPHARM Oncology (NASDAQ:ZIOP) stock declined by 7.41% to $1.25 during Friday's after-market session. Trading volume for this security closed at 2.1 million, accounting for 98.84% of its average full-day volume over the last 100 days. The company's market cap stands at $270.1 million.
    • SINTX Technologies (NASDAQ:SINT) stock fell 6.48% to $0.65. The market value of their outstanding shares is at $16.0 million.
    • Global Blood Therapeutics (NASDAQ:GBT) shares fell 4.72% to $29.11. At the close, Global Blood Therapeutics's trading volume reached 806.7K shares. This is 53.21% of its average volume over the last 100 days. The market value of their outstanding shares is at $1.8 billion.
    • Bellerophon Therapeutics (NASDAQ:BLPH) shares decreased by 4.71% to $3.04. At the close, Bellerophon Therapeutics's trading volume reached 138.3K shares. This is 335.29% of its average volume over the last 100 days. The company's market cap stands at $28.8 million.
    • Eloxx Pharmaceuticals (NASDAQ:ELOX) stock declined by 4.39% to $0.71. Trading volume for this security closed at 66.0K, accounting for 10.95% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $60.9 million.
    • ASLAN Pharmaceuticals (NASDAQ:ASLN) shares declined by 4.07% to $1.18. The company's market cap stands at $82.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AMRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AMRX
    $ASLN
    $BBI
    $BLPH

    CompanyDatePrice TargetRatingAnalyst
    Amneal Pharmaceuticals Inc.
    $AMRX
    12/9/2025$15.00Overweight
    Barclays
    Corvus Pharmaceuticals Inc.
    $CRVS
    10/13/2025$16.00Overweight
    Barclays
    Amneal Pharmaceuticals Inc.
    $AMRX
    6/6/2025$12.00Buy
    Goldman
    Amneal Pharmaceuticals Inc.
    $AMRX
    2/24/2025$9.00 → $12.00Neutral → Overweight
    Analyst
    Corvus Pharmaceuticals Inc.
    $CRVS
    1/2/2025$11.00Buy
    H.C. Wainwright
    Amneal Pharmaceuticals Inc.
    $AMRX
    9/6/2024$9.00Underweight → Neutral
    JP Morgan
    Corvus Pharmaceuticals Inc.
    $CRVS
    8/18/2023$7.00Outperform
    Oppenheimer
    Global Blood Therapeutics Inc.
    $GBT
    8/8/2022Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $AMRX
    $ASLN
    $BBI
    $BLPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Amneal Pharmaceuticals with a new price target

    Barclays initiated coverage of Amneal Pharmaceuticals with a rating of Overweight and set a new price target of $15.00

    12/9/25 8:42:32 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Corvus Pharmaceuticals with a new price target

    Barclays initiated coverage of Corvus Pharmaceuticals with a rating of Overweight and set a new price target of $16.00

    10/13/25 8:52:40 AM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on Amneal Pharmaceuticals with a new price target

    Goldman initiated coverage of Amneal Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    6/6/25 8:33:10 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    $ASLN
    $BBI
    $BLPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

    Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth. The update follows a series of key developments, including the successful completion of the first human surgical procedure us

    3/23/26 9:15:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Announces First-In-Human Surgery Using FDA-Cleared SINAPTIC® Foot & Ankle Implant

    Major clinical milestone marks SINTX's entry into the foot and ankle reconstruction market and advances commercialization of its silicon nitride biomaterial platform SALT LAKE CITY, Utah, March 19, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), a leader in advanced ceramic biomaterials and silicon nitride medical device innovation, today announced the successful completion of the first-in-human surgical procedure utilizing its FDA-cleared SINAPTIC® Foot & Ankle Osteotomy Wedge System, marking a major clinical and commercial milestone in the Company's expansion into the global orthopedic device market. The procedure represents SINTX's entry int

    3/19/26 7:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated soquelitinib atopic dermatitis Phase 2 trial Completed public offering raising net proceeds of $189 million, extending cash runway into the second quarter of 2028 Conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended De

    3/12/26 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    $ASLN
    $BBI
    $BLPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $AMRX
    $ASLN
    $BBI
    $BLPH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Corvus Pharmaceuticals Inc.

    SCHEDULE 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

    3/26/26 5:39:01 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Amneal Pharmaceuticals Inc.

    SCHEDULE 13G/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

    3/26/26 3:43:45 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Amneal Pharmaceuticals Inc.

    DEFA14A - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)

    3/25/26 4:16:09 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    $ASLN
    $BBI
    $BLPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Patel Chintu

    4/A - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

    3/27/26 4:20:46 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Patel Chirag K.

    4/A - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

    3/27/26 4:19:46 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Ew Healthcare Partners, L.P.

    4 - Venus Concept Inc. (0001409269) (Issuer)

    3/27/26 4:05:02 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $AMRX
    $ASLN
    $BBI
    $BLPH
    Financials

    Live finance-specific insights

    View All

    Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

    SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 12, 2026 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus' website for 90 d

    3/5/26 4:01:00 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amneal Reports Fourth Quarter and Full Year 2025 Financial Results

    ‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million; GAAP Net Income of $35 million; Diluted Income per Share of $0.11 ‒ ‒ Q4 2025 Adjusted Net Income of $68 million, Adjusted EBITDA of $175 million; Adjusted Diluted EPS of $0.21 ‒ ‒ Full Year 2025 Net Revenue of $3.02 billion; GAAP Net Income of $72 million; Diluted Income per Share of $0.22 ‒ ‒ Full Year 2025 Adjusted Net Income of $269 million; Adjusted EBITDA of $688 million; Adjusted Diluted EPS of $0.83 ‒ ‒ Provides 2026 Financial Guidance of $3.05 to $3.15 billion in net revenue, $720 to $760 million in Adjusted EBITDA, and $0.93 to $1.0

    2/27/26 6:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amneal to Report Fourth Quarter and Full Year 2025 Results on February 27, 2026

    BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit t

    1/27/26 8:00:00 AM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AMRX
    $ASLN
    $BBI
    $BLPH
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

    Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth. The update follows a series of key developments, including the successful completion of the first human surgical procedure us

    3/23/26 9:15:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

    NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE:CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE:SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions. SM Energy will remain in the S&P SmallCap 600 post-merger.Dutch Bros Inc. (NYSE:BROS) will replace Potlatc

    1/27/26 6:02:00 PM ET
    $AEIS
    $AHR
    $AMRX
    Industrial Machinery/Components
    Technology
    Real Estate Investment Trusts
    Real Estate

    $AMRX
    $ASLN
    $BBI
    $BLPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Amneal Pharmaceuticals Inc.

    SC 13G/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

    11/14/24 4:11:34 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Amneal Pharmaceuticals Inc.

    SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

    10/31/24 6:51:29 PM ET
    $AMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care